• linkedin
  • Increase Font
  • Sharebar

    When other treatments fail in atopic dermatitis, dupilumab succeeds

    Dupilumab plus topical corticosteroids safe and effective after failure of cyclosporine in moderate-to-severe atopic dermatitis




    • Dupilumab combined with topical corticosteroids improved measures of overall disease severity vs placebo in patients who were inadequately controlled or intolerant of CSA, or did not receive the immunosuppressive treatment due to medical concerns.
    • Conjunctivitis was more frequent in patients who received dupilumab with TCS, but overall, the proportion of patients reporting an adverse event was similar among dupilumab and placebo arms.
    • Dupilumab plus TCS may be a good alternative to CSA in this difficult-to-treat population for whom there are few treatment options.



    Dr. Thaçi reports he has been investigator, member of medical advisory board, and speaker for Regeneron/Sanofi.



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow